Cambridge Healthtech Institute’s 7th Annual

Immunomodulatory Therapeutic Antibodies for Cancer

Emerging Targets, Combinations, and Antibody Engineering for Next-Generation Immunotherapy

August 5-6, 2019

Despite the success of immunomodulatory antibodies in immuno-oncology, challenges remain in expanding the target space, engineering next-generation antibodies with improved efficacy and safety, and addressing innate and acquired resistance to immunotherapy. CHI’s Seventh Annual Immunomodulatory Therapeutic Antibodies for Cancer conference will explore next-generation immunotherapies, emerging targets and combinations, and strategies for overcoming resistance. It will provide case studies of antibody development in immuno-oncology from preclinical to clinical development.

EMERGING TARGETS FOR IMMUNOMODULATORY ANTIBODIES

Next-Generation Immune Checkpoints – Deciphering Key Roles in the TME
Catherine Sabatos-Peyton, PhD, Director, Exploratory Immuno-Oncology, Novartis

Personalizing Checkpoint Inhibition in Melanoma
Justin Balko, PharmD, PhD, Assistant Professor, Medicine & Cancer Biology, Vanderbilt University School of Medicine

Anti-LAP Antibodies in Oncology
Jessie English, PhD, CSO, Tilos Therapeutics

ATOR-1017, a Tumor-Directed Fcγ-Receptor Cross-Linking Dependent 4-1BB Agonistic Antibody
Christina Furebring, PhD, Senior Vice President, R&D, Alligator Bioscience

STRATEGIES TO IMPROVE RESPONSE TO IMMUNOMODULATORS

Intratumoral Anchoring of Immunomodulators Potentiates Systemic Immunotherapy
K. Dane Wittrup, PhD, Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology

Targeting Wnt Ligand Signaling as a Strategy for Overcoming Resistance to Anti-PD-1 Antibody Immunotherapy
Brent Hanks, MD, PhD, Assistant Professor, Medicine, Assistant Professor, Pharmacology and Cancer Biology, Duke Cancer Institute, Duke University School of Medicine

COMBINATION STRATEGIES TO INCREASE RESPONSE TO CHECKPOINT MODULATORS

Induction of Durable Regression in PD-1 Refractory Melanoma Following Intratumoral Injection of a CpG-A TLR9 Agonist, CMP-001 in Combination with Systemic Pembrolizumab
Arthur Krieg, MD, Founder & CSO, Checkmate Pharmaceuticals

Immunotherapy Combinations: Lessons Learned and Future Outlook
Maria Karasarides, PhD, Executive Director, Immuno-Oncology Global Development, Regeneron Pharmaceuticals

Combination of NKTR-214 and Opdivo
Wei Lin, PhD, Senior Vice President, Oncology Development, Nektar Therapeutics

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com